Here, we analyzed a large cohort of patients with NSCLC and matched pre- and post-ICI samples to characterize the genomic and immunophenotypic landscape of AR to PD-(L)1 inhibition. The gene discussed is AR; the disease is non-small cell lung carcinoma.